Morgan Stanley Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price

Key Points

• Morgan Stanley cut its BioNTech price target from $114 to $106 but maintained an Overweight rating; the new target implies 17.37% upside from the share price cited.
• Analyst sentiment remains broadly positive: BioNTech has a consensus “Moderate Buy” rating and an average price target of $124.27, despite differing target revisions and one Sell rating.
• BioNTech’s latest reported quarter in the article missed expectations, with an EPS loss of $2.53 versus a $2.40 loss forecast and revenue of $122.31 million versus $180.18 million expected; revenue fell 59.5% year over year.

BioNTech (NASDAQ:BNTX - Get Free Report) had its price objective reduced by research analysts at Morgan Stanley from $114.00 to $106.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has an "overweight" rating on the stock. Morgan Stanley's target price suggests a potential upside of 17.37% from the company's current price.

BNTX has been the topic of a number of other research reports. Bank of America reissued a "buy" rating on shares of BioNTech in a research note on Wednesday. UBS Group reiterated a "buy" rating on shares of BioNTech in a research report on Wednesday, September 16th. Canaccord Genuity Group reduced their target price on shares of BioNTech from $136.00 to $132.00 and set a "buy" rating on the stock in a report on Wednesday, October 14th. Wall Street Zen cut BioNTech from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Finally, Berenberg Bank set a $140.00 target price on BioNTech in a research note on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $124.27.

BioNTech Price Performance

BNTX traded up $3.39 on Wednesday, reaching $90.31. The company had a trading volume of 748,094 shares, compared to its average volume of 1,091,199. The business has a 50 day simple moving average of $96.14 and a 200 day simple moving average of $96.99. The company has a market cap of $22.84 billion, a price-to-earnings ratio of -11.54 and a beta of 1.28. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. BioNTech has a 52-week low of $79.52 and a 52-week high of $124.00.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million during the quarter, compared to analysts' expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. BioNTech's quarterly revenue was down 59.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.60) EPS. As a group, sell-side analysts anticipate that BioNTech will post -6.62 EPS for the current year.

Insider Transactions at BioNTech

In other BioNTech news, CEO Ugur Sahin sold 72,000 shares of the company's stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the completion of the transaction, the chief executive officer owned 108,209 shares of the company's stock, valued at $10,521,161.07. This represents a 39.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 807,209 shares of company stock worth $79,246,837. 19.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Flossbach Von Storch SE bought a new stake in BioNTech during the second quarter valued at about $207,142,000. Bank of America Corp DE grew its stake in BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock valued at $80,261,000 after acquiring an additional 166,432 shares during the period. First Trust Advisors LP increased its holdings in shares of BioNTech by 116.0% during the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock worth $74,658,000 after buying an additional 451,124 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of BioNTech by 79.7% during the third quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company's stock worth $74,774,000 after buying an additional 337,412 shares in the last quarter. Finally, Candriam S.C.A. increased its holdings in BioNTech by 4.7% during the 3rd quarter. Candriam S.C.A. now owns 520,972 shares of the company's stock valued at $51,399,000 after acquiring an additional 23,442 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech News Summary

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Q3 results topped expectations: BioNTech reported earnings of $1.99 per share versus the $0.76 consensus and revenue of $1.49 billion versus $1.17 billion expected. The company also raised its 2026 revenue guidance to €1.7–€1.9 billion. Article: BioNTech beats third-quarter forecasts and raises revenue guidance despite pipeline setbacks
• Positive Sentiment: Oncology data and upcoming catalysts: BioNTech reported promising gotistobart results in previously treated squamous lung cancer and expects an interim analysis before year-end. It is also advancing pumitamig combination trials. These programs could support its longer-term shift toward oncology. Article: BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
• Neutral Sentiment: Wells Fargo lowered its target but kept an Overweight rating: The firm cut its price target from $140 to $125, while its revised target still implies substantial upside from the share price cited in the report. Article: Wells Fargo & Company stock recommendations
• Negative Sentiment: Revenue remains pressured and pipeline risk persists: Q3 revenue fell 15.1% year over year amid lower COVID-19 vaccine demand. A bearish analysis cited ongoing cash burn, a narrowing pipeline, and increasing reliance on pumitamig and gotistobart, raising concerns about the sustainability of the oncology strategy. Article: BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company's research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech's oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.